Έρευνα

Lung microbiome: an emerging player in lung cancer pathogenesis and progression.
Karvela A, Veloudiou OZ, Karachaliou A, Kloukina T, Gomatou G, Kotteas E.Clin Transl Oncol. 2023

Impact of biologic therapies on risk of adverse cardiovascular events in patients with Ankylosing Spondylitis or Psoriatic Arthritis: A systematic literature review.
Magiouf KS, Fragiadaki K, Charpidou A, Syrigos A, Kotteas E, Kourlaba G.ARP Rheumatol. 2023

Pulmonary benign metastasizing leiomyoma: A case report.
Panagiotou E, Vamvakaris I, Syrigos N, Kotteas E. Monaldi Arch Chest Dis. 2023

Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options.
Gomatou G, Syrigos N, Kotteas E. Cancers. 2023

Emerging therapies in thymic epithelial tumors (Review).
Dapergola A, Gomatou G, Trontzas I, Panagiotou E, Dimakakos E, Syrigos N, Kotteas E. Oncol Lett. 2023

Bcl-2 pathway inhibition in solid tumors: a review of clinical trials.
Ploumaki I, Triantafyllou E, Koumprentziotis IA, Karampinos K, Drougkas K, Karavolias I, Trontzas I, Kotteas EA. Clin Transl Oncol. 2023

Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?
Drougkas K, Karampinos K, Karavolias I, Koumprentziotis IA, Ploumaki I, Triantafyllou E, Trontzas I, Kotteas E.J Cancer Res Clin Oncol. 2023

Programmed Cell Death Protein 1 Axis Inhibition in Viral Infections: Clinical Data and Therapeutic Opportunities.
Tsiakos K, Gavrielatou N, Vathiotis IA, Chatzis L, Chatzis S, Poulakou G, Kotteas E, Syrigos NK.Vaccines. 2022

CD24: A Novel Target for Cancer Immunotherapy.
Panagiotou E, Syrigos NK, Charpidou A, Kotteas E, Vathiotis IA. J Pers Med. 2022

Immune Checkpoint Blockade in Hormone Receptor-Positive Breast Cancer: Resistance Mechanisms and Future Perspectives.
Vathiotis IA, Trontzas I, Gavrielatou N, Gomatou G, Syrigos NK, Kotteas EA. Clin Breast Cancer. 2022

Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations-State-of-the-Art.
Dimakakos E, Gomatou G, Catalano M, Olinic DM, Spyropoulos AC, Falanga A, Maraveyas A, Liew A, Schulman S, Belch J, Gerotziafas G, Marschang P, Cosmi B, Spaak J, Syrigos K; CANCER-COVID-19 THROMBOSIS COLLABORATIVE GROUP. Anticancer Res. 2022

Serum and Pleural Soluble Cell Adhesion Molecules in Mesothelioma Patients: A Retrospective Cohort Study.
Tsagkouli S, Kyriakoulis IG, Kyriakoulis KG, Fyta E, Syrigos A, Bakakos P, Charpidou A, Kotteas E. Cancers (Basel). 2022

Acute and Late Rectal Toxicity Following Hypofractionated Radiotherapy in Patients With Prostate Cancer: Results of a Prospective Study.
Kounadis G, Syrigos N, Kougioumtzopoulou A, Bamias G, Kotteas I, Papatheodoridis G, Grapsa D.In Vivo

BRAF/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it.
Tsamis I, Gomatou G, Chachali SP, Trontzas IP, Patriarcheas V, Panagiotou E, Kotteas E.Clin Transl Oncol. 2023

Significant Increase in Blood Pressure Following BNT162b2 mRNA COVID-19 Vaccination among Healthcare Workers: A Rare Event.
Syrigos N, Kollias A, Grapsa D, Fyta E, Kyriakoulis KG, Vathiotis I, Kotteas E, Syrigou E.Vaccines (Basel). 2022

Assessment of Seroconversion after SARS-CoV-2 Vaccination in Patients with Lung Cancer.
Trontzas IP, Vathiotis I, Economidou C, Petridou I, Gomatou G, Grammoustianou M, Tsamis I, Syrigos N, Anagnostakis M, Fyta E, Sakka V, Poulakou G, Kotteas EA, Syrigou E.Vaccines (Basel). 2022

Differential immunohistochemical expression of hTERT in lung cancer patients with and without idiopathic pulmonary fibrosis.
Gomatou G, Masaoutis C, Vamvakaris I, Kotteas E, Bouros E, Tzilas V, Bouros D. Pulmonology. 2022.

Central-line-associated bloodstream infections, multi-drug-resistant bacteraemias and infection control interventions: a 6-year time-series analysis in a tertiary care hospital in Greece.
Papanikolopoulou A, Maltezou HC, Gargalianos-Kakolyris P, Michou I, Kalofissoudis Y, Moussas N, Pantazis N, Kotteas E, Syrigos KN, Pantos C, Tountas Y, Tsakris A, Kantzanou M.J Hosp Infect. 2022

Capecitabine-associated enterocolitis: Narrative literature review of a rare adverse event and a case presentation.
Trontzas IP, Rapti VE, Syrigos NK, Gomatou G, Lagou S, Kanellis G, Kotteas EA.J Chemother. 2023

Malignant Superior Vena Cava Syndrome: State of the Art.
Patriarcheas V, Grammoustianou M, Ptohis N, Thanou I, Kostis M, Gkiozos I, Charpidou A, Trontzas I, Syrigos N, Kotteas E, Dimakakos E. Cureus 2022

Pulmonary blastoma: a comprehensive overview of a rare entity.
Tsamis I, Chachali SP, Gomatou G, Trontzas I, Mitsogianni M, Syrigos N, Vamvakaris I, Kotteas E.Adv Respir Med. 2021

A case of trastuzumab-induced dermatomyositis.
Trontzas IP, Syrigos NK, Kotteas EA.J Cancer Res Ther. 2021

Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials.
Panagiotou E, Gomatou G, Trontzas IP, Syrigos N, Kotteas E.Clin Transl Oncol. 2022

Enteric plexus neuropathy associated with PD-L1 blockade in a patient with small-cell lung cancer.
Trontzas IP, Rapti VE, Syrigos NK, Kounadis G, Perlepe N, Kotteas EA, Bamias G.Immunotherapy. 2021

Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group.
Fountzilas E, Lampaki S, Koliou GA, Koumarianou A, Levva S, Vagionas A, Christopoulou A, Laloysis A, Psyrri A, Binas I, Mountzios G, Kentepozidis N, Kotsakis A, Saloustros E, Boutis A, Nikolaidi A, Fountzilas G, Georgoulias V, Chrysanthidis M, Kotteas E, Vo H, Tsiatas M, Res E, Linardou H, Daoussis D, Bompolaki I, Andreadou A, Papaxoinis G, Spyratos D, Gogas H, Syrigos KN, Bafaloukos D. Cancer Immunol Immunother. 2022

Tumor Dormancy: Implications for Invasion and Metastasis.
Gomatou G, Syrigos N, Vathiotis IA, Kotteas EA.Int J Mol Sci.

Risk Factors for Venous Thromboembolism in Patients With Small Cell Lung Cancer.
Dimakakos E, Livanios K, Vathiotis I, Gomatou G, Gkiozos I, Kotteas E, Kainis E, Syrigos K.Anticancer Res. 2021

The changing treatment of metastatic her2-positive breast cancer.
Mitsogianni M, Trontzas IP, Gomatou G, Ioannou S, Syrigos NK, Kotteas EA. Oncol Lett. 2021

Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors.
Gomatou G, Trontzas I, Ioannou S, Drizou M, Syrigos N, Kotteas E. Mol Biol Rep. 2021

Immune Checkpoint Inhibitor-Related Pneumonitis.
Gomatou G, Tzilas V, Kotteas E, Syrigos K, Bouros D. Respiration. 2020

Modern radiopharmaceuticals for lung cancer imaging with positron emission tomography/computed tomography scan: A systematic review.
Theodoropoulos AS, Gkiozos I, Kontopyrgias G, Charpidou A, Kotteas E, Kyrgias G, Tolia M. SAGE Open Med.

Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors.
Sollena P, Nikolaou V, Soupos N, Kotteas E, Voudouri D, Stratigos AJ, Fattore D, Annunziata MC, Orlandi A, Di Nardo L, Apalla Z, Deilhes F, Romano MC, Fabbrocini G, Sibaud V, Peris K; European Network for Cutaneous ADverse event of Oncologic drugs (ENCADO) group.Breast Cancer Res Treat. 2021

Do we need prophylactic anticoagulation in ambulatory patients with lung cancer? A review.
Dimakakos E, Kotteas E, Gomatou G, Katsarou T, Vlahakos V, Vathiotis I, Talagani S, Dimitroulis I, Syrigos K. Vasc Med. 2020

Orbital metastases of invasive lobular breast carcinoma.
Tsagkaraki IM, Kourouniotis CD, Gomatou GL, Syrigos NK, Kotteas EA. Breast Dis. 2019

Towards precision medicine: CCL2, another brick in the wall?
Charpidou A, Kotteas E, Gaga M. Eur Respir J. 2019

PET/CT and brain MRI role in staging NSCLC: prospective assessment of the accuracy, reliability and cost-effectiveness.
Gkogkozotou VI, Gkiozos IC, Charpidou AG, Kotteas EA, Boura PG, Tsagouli SN, Syrigos KN. Lung Cancer Manag. 2018

Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.
Syrigos K, Grapsa D, Sangare R, Evmorfiadis I, Larsen AK, Van Dreden P, Boura P, Charpidou A, Kotteas E, Sergentanis TN, Elalamy I, Falanga A, Gerotziafas GT. Oncologist. 2018

Lung Metastasis From Fibrosarcomatous Dermatofibrosarcoma Protuberans of the Vulva: A Rare Case Report.
Vathiotis IA, Psichogiou E, Syrigos KN, Kotteas EA. J Low Genit Tract Dis. 2018

Optimizing diet and nutrition for cancer survivors: A review.
Mourouti N, Panagiotakos DB, Kotteas EA, Syrigos KN. Maturitas. 2018

Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it.
Drizou M, Kotteas EA, Syrigos N. Clin Transl Oncol. 2017

The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review.
Ntanasis-Stathopoulos I, Fotopoulos G, Tzanninis IG, Kotteas EA. Cancer Invest. 2016

Management and Outcomes in Metaplastic Breast Cancer.
Tzanninis IG, Kotteas EA, Ntanasis-Stathopoulos I, Kontogianni P, Fotopoulos G. Clin Breast Cancer. 2016

Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors.
Kotteas EA, Syrigos KN, Saif MW. Onco Targets Ther. 2016

Immunotherapy for pancreatic cancer.
Kotteas E, Saif MW, Syrigos K. J Cancer Res Clin Oncol. 2016

Neuroendocrine Merkel cell nodal carcinoma of unknown primary site: management and outcomes of a rare entity.
Kotteas EA, Pavlidis N. Crit Rev Oncol Hematol. 2015

The intercellular cell adhesion molecule-1 (icam-1) in lung cancer: implications for disease progression and prognosis.
Kotteas EA, Boulas P, Gkiozos I, Tsagkouli S, Tsoukalas G, Syrigos KN.Anticancer Res. 2014

Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group.
Pentheroudakis G, Kotteas EA, Kotoula V, Papadopoulou K, Charalambous E, Cervantes A, Ciuleanu T, Fountzilas G, Pavlidis N. Clin Exp Metastasis. 2014

Soluble ICAM-1 levels in small-cell lung cancer: prognostic value for survival and predictive significance for response during chemotherapy.
Kotteas EA, Gkiozos I, Tsagkouli S, Bastas A, Ntanos I, Saif MW, Syrigos KN.Med Oncol. 2013;

A pregnant patient with adrenocortical carcinoma: case report.
Kotteas E, Ioachim E, Pavlidis N. Onkologie. 2012

Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol.
Syrigou E, Dannos I, Kotteas E, Makrilia N, Tourkantonis I, Dilana K, Gkiozos I, Saif MW, Syrigos KN.Int Arch Allergy Immunol. 2011

Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors.
Kotteas EA, Charpidou AG, Syrigos KN.Anticancer Drugs. 2010

Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study.
Ralli M, Tourkantonis I, Makrilia N, Gkini E, Kotteas E, Gkiozos I, Katirtzoglou N, Syrigos K.Anticancer Res. 2009

Gastrointestinal bleeding as initial presentation of melanoma of unknown primary origin: report of a case and review of the literature.
Kotteas EA, Adamopoulos A, Drogitis PD, Zalonis A, Giannopoulos KV, Karapanagiotou EM, Saif MW, Syrigos KN.In Vivo. 2009

Adhesion molecules in lung cancer: implications in the pathogenesis and management.
Syrigos KN, Katirtzoglou N, Kotteas E, Harrington K. Curr Pharm Des. 2008

Safety and efficacy of zoledronic acid rapid infusion in lung cancer patients with bone metastases: a single institution experience.
Kotteas E, Alamara C, Kiagia M, Pantazopoulos K, Boufas A, Provata A, Charpidou A, Syrigos KN. Anticancer Res. 2008

Targeted therapy for oesophageal cancer: an overview.
Syrigos KN, Zalonis A, Kotteas E, Saif MW. Cancer Metastasis Rev. 2008

A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer.
Karapanagiotou EM, Charpidou A, Tzannou I, Dilana K, Kotteas E, Tourkantonis I, Kosmas E, Provata A, Syrigos K. Med Oncol. 2008

Pegylated Liposomal Doxorubicin HCL (Caelyx) in combination with Sandostatin LAR as salvage therapy in patients with small-cell lung cancer.
Charpidou A, Hatzidarellis EP, Alamara C, Dilana K, Pantazopoulos K, Kotteas E, Georgatou N, Syrigos KN. In Vivo. 2006